You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百奧賽圖(02315.HK)與楊森達成非獨家授權協議
阿思達克 03-08 16:35
百奧賽圖(02315.HK)公布,與楊森製藥公司下屬楊森生物技術公司達成非獨家授權協議。根據授權協議,百奧賽圖授予楊森及其關聯公司全球非獨家許可,使用百奧賽圖專有RenLite平臺及其相關知識產權,以發現、研究、開發和商業化可為數量不限的藥物靶點和適應症服務的全人共輕鏈抗體療法和其他生物療法。該協議由強生創新主導。 截至去年6月30日,百奧賽圖自主研發的全人抗體RenMice(R)平臺已與全球16間生物製藥公司達成授權使用協議,包括德國默克、Xencor、百濟神州、信達生物等;集團已經達成28個抗體分子授權轉讓/合作開發交易,僅去年上半年新增11個交易。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account